Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBOP study of brigatinib plus panitumumab in osimertinib-resistant EGFR-mutated non-small cell lung cancer
jRCT2031200231Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of brigatinib and panitumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicities and Objective response rate. Started Dec 2020; status: completed.
02
Drugs
brigatinibpanitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031200231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200231.